Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma

Recruiting

Phase 2

Pembrolizumab & LenvatinibPembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma

Sponsor:

Diwakar Davar

Code:

NCT06030037

Conditions

PD-1 Refractory Advanced Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Healthy Donor Fecal Microbiota Transplantation (hdFMT)

Pembrolizumab

Lenvatinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-30. This information was provided to ClinicalTrials.gov by Diwakar Davar on 2025-03-13.